Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 17;28(3):196-198.
doi: 10.1093/oncolo/oyac270.

HiJAKing Immunotherapy-Resistant Melanoma for a Cure

Lewis Zhichang Shi  1   2   3   4   5 , Hongxing Shen  1 , Oluwagbemiga A Ojo  1 , James A Bonner  1   2
Affiliations

HiJAKing Immunotherapy-Resistant Melanoma for a Cure

Lewis Zhichang Shi et al. Oncologist. .

Abstract

Immune checkpoint blockers (ICBs) have brought great promise to patients with advanced melanoma, a tumor type that was claimed largely incurable not long ago. However, therapeutic resistance to ICBs has limited their utility in the clinic. Here, we provide a commentary on recent research endeavors concerning ICB resistance in melanoma patients.

Keywords: JAK inhibition (JAKi); immune checkpoint blockers; melanoma.

PubMed Disclaimer

Conflict of interest statement

The authors indicated no financial relationships.

Figures

Figure 1.
Figure 1.
The mTOR-JAK1/2 is a therapeutic target to overcome ICB resistance in melanoma defective of IFN-γ signaling. Abbreviations: IFN γ R1KO, knockout of the essential IFN- γ receptor 1; mTOR, the mechanistic target of rapamycin, a master regulator of cellular metabolism; JAK1/2, Janus kinases 1&2, essential kinases in the IFN-γ signaling; Ruxo, Ruxolitinib, an FDA-approved JAK1/2 inhibitor; Teff, effector T cells (eg, TNF-producing T cells); Treg, FoxP3+ regulatory T cells; ICB: immune checkpoint blocker.
See this image and copyright information in PMC

References

    1. Hodi FS, O’Day SJ, McDermott DF, et al. . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723. - PMC - PubMed
    1. Curran MA, Montalvo W, Yagita H, et al. . Pd-1 and ctla-4 combination blockade expands infiltrating T cells and reduces regulatory t and myeloid cells within b16 melanoma tumors. Proc Natl Acad Sci USA. 2010;107(9):4275-4280. - PMC - PubMed
    1. Peggs KS, Quezada SA, Korman AJ, Allison JP.. Principles and use of anti-ctla4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18(2):206-213. 10.1016/j.coi.2006.01.011. - DOI - PubMed
    1. Shi LZ, Fu T, Guan B, et al. . Interdependent il-7 and ifn-gamma signalling in t-cell controls tumour eradication by combined alpha-ctla-4+alpha-pd-1 therapy. Nat Commun. 2016;7(1):12335. - PMC - PubMed
    1. Shen H, Yang ES-H, Conry M, et al. . Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. Genes & Diseases. 2019;6(3):232-246. - PMC - PubMed

Publication types

MeSH terms

Substances